Johnson Health Tech .Co Full Year 2023 Earnings: EPS Misses Expectations

Johnson Health Tech .Co (TWSE:1736) Full Year 2023 Results

Key Financial Results

• Revenue: NT$38.1b (up 13% from FY 2022).
• Net income: NT$709.8m (up 66% from FY 2022).
• Profit margin: 1.9% (up from 1.3% in FY 2022). The increase in margin was driven by higher revenue.
• EPS: NT$2.34 (up from NT$1.42 in FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Johnson Health Tech .Co EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 18%.

Looking ahead, revenue is forecast to grow 5.4% p.a. on average during the next 2 years, compared to a 3.8% growth forecast for the Leisure industry in Taiwan.

Performance of the Taiwanese Leisure industry.

The company's shares are down 2.1% from a week ago.

Risk Analysis

It's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with Johnson Health Tech .Co, and understanding it should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.